Paraprotein interference with turbidimetric gentamicin assay by Goce Dimeski et al.
©Copyright by Croatian Society of Medical Biochemistry and Laboratory Medicine. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License 
(http://creativecommons.org/licenses/by-nc-nd/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
http://dx.doi.org/10.11613/BM.2015.014 Biochemia Medica 2015;25(1):117–24 
  117
Abstract
Introduction: Gentamicin due to its low level of resistance and rapid bactericidal activity is commonly used to treat gram-negative bacteria. Howe-
ver, due to its toxic effects it needs to be monitored. To date, no interference has been reported with gentamicin assays.  
Materials and methods: A patient with leg cellulitis and sepsis received a single dose of gentamicin and a sample was sent for gentamicin 
analysis. The sample showed high blank absorbance readings on Beckman DxC800 and DC800 analysers with various dilutions. A second sample was 
received and analysed on a Roche Cobas system to obtain a result. A third sample was received 107 hours later with the same results and this sample 
was then analysed neat and post ethanol precipitation on all the turbidimetric assays available on the DxC800 analyser. 
Results: The high blank absorbance was observed upon addition of the reactive reagents due to protein precipitation. Although not obvious from 
the patient protein results, it was shown the presence of high IgM paraprotein, 18.9 g/L (reference range 0.4-2.3 g/L) was the cause of precipitation, 
giving high blank readings. Of all the other turbidimetric assays, only vancomicin and valproate showed similar high blank absorbance readings. To 
be able to provide more rapid results it was shown ethanol could be used as a precipitant of proteins in both calibrators and patient samples with 
acceptable recovery. 
Conclusion: IgM paraprotein was identified as the cause of interference with the gentamicin, vancomicin and valproate assays. Protein interference 
in these assays can be overcome by precipitation with ethanol.  
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Gentamicin belongs to the aminoglycosides group 
of antibiotics which are among the oldest antibiot-
ics available to treat serious infections caused pri-
marily by gram-negative bacteria. When the use of 
aminoglycosides became more widespread, the 
toxic effects, ototoxicity and nephrotoxicity, be-
came more apparent and there was a switch to 
other, safer, antimicrobial agents, and the use of 
aminoglycosides sharply declined. However, the 
development of multi-drug resistance among bac-
teria has now led to resurgent use of the amino-
glycosides in the treatment of serious infections. 
Not only does gentamicin offer comparable low 
levels of resistance but it is rapid in its bactericidal 
activity. However due to toxicity, there is a need to 
monitor plasma concentrations to prevent the rare 
occurrence of sudden idiosyncratic deafness and 
nephrotoxicity with prolong therapy (1,2). Even 
though guidelines exist for monitoring plasma 
concentrations (3) a recent study reported 20% of 
collected samples were outside the required sam-
pling window (6 -14 hours post dose), and 15% of 
doses were adjusted without monitoring and ap-
proximately half of all dose adjustments were 
based on inadequate information or inaccurate 
nomogram interpretation (4). 
Serum protein abnormalities have been shown to 
interfere with turbidimetric assays such as vanc-
omicin on the Beckman DxC800 general chemis-
try analyzer (5). Interferences have also been re-
ported with other turbidimetric assays, C-reactive 
protein (6,7) phenytoin (8), and transferrin (9), as 
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well as with nephelometric assays, IgA and IgG 
(10), and other non turbidimetric/nephelometric 
assays such as total bilirubin (11), thyroid-stimulat-
ing hormone (12), lactate dehydrogenase, uric acid 
and alkaline phosphatase (13), glucose and gam-
ma-glutamyl transferase (14), HDL-cholesterol and 
as well as glucose interference being observed 
with glucose analyses on a hexokinase method 
but not on an oxidase method (15). From our 
searches no such interferences have been report-
ed with gentamicin. 
Materials and methods
Case
A 93 year old female with severe dementia pre-
sented with leg cellulitis and sepsis and was ad-
ministered 320 mg gentamicin (Pfizer, Perth, Aus-
tralia) at one of our smaller hospitals. No further 
gentamicin was administered during her hospital 
stay. On presentation the patient’s sample was an-
alysed on a Beckman DxC600 general chemistry 
analyser (Beckman Coulter, Brea, CA, USA) as per 
Beckman Coulter recommendations and the re-
sults were: creatinine 177 µmol/L (reference range 
(RR) 46-108), urea 12.0 mmol/L (RR 2.9-8.2), total 
protein 63 g/L (RR 60-83), albumin 22 g/L (RR 35-
50), and globulins 41 g/L (RR 25-45). A blood sam-
ple was collected ~40 hours post gentamicin ad-
ministration and the laboratory could not obtain a 
result due to persistent high blank absorbance er-
rors on the Beckman DxC600 general chemistry 
analyzer (Beckman Coulter, Brea, CA, USA). The 
sample was diluted with normal saline with ratios 
starting from 1/3 and going as high as 1/20. The 
sample was then referred to our laboratory and di-
lutions were repeated on a Beckman DxC800 gen-
eral chemistry analyzer using the exact same 
method. The absorbance error could not be elimi-
nated to obtain a result as shown by the absorb-
ance curves in Figure 1. A second sample was then 
collected at ~50 hours post gentamicin adminis-
tration and this was dispatched for analysis on a 
Roche Cobas system (Roche Diagnostics, Mannhe-
im, Germany) and the result was 3.3 mg/L. No fur-
ther gentamicin was administered. Review of the 
absorbance curves suggested an interference re-
lated problem. Although the total protein level did 
not suggest presence of paraproteins the globu-
lins level was high enough not to rule out the pres-
ence of paraproteins. The sample was then diluted 
off board with the reagent A (reaction buffer) in 
the ratio used in the method and no precipitation 
was observed. Unfortunately by this stage due to 
limited volume no further tests could be conduct-
ed. 
A third sample was received at ~107 hours post 
gentamicin administration and the gentamicin re-
sult on the Roche Cobas method was 1.2 mg/L. 
The remaining portion of this sample was ana-
lysed for all the turbidimetric assays utilised on the 
Beckman DxC800: C-RP, carbamazepine, digoxin, 
haptoglobin, phenytoin, transferrin, tobramycin, 
theophylline, valproate, vancomicin, to see if any 
of these would exhibit any limitations. Like the 
gentamicin method all these methods are particle 
enhanced turbidimetric inhibition immunoassay 
methods. Only vancomicin and valproate showed 
high blank absorbance readings. Additionally the 
sample was analysed for immunoglobulins (rheu-
matoid factor, IgA, IgG and IgM) by nephelometry 
on a BNTM II System (Siemens Diagnostic, Deer-
field, IL, USA) as per manufacturer recommenda-
tions. 
To determine if a suitable precipitation method 
could be implemented to provide more rapid re-
sults the Beckman calibrator sets for each of the 
three assays were precipitated to ensure accuracy is 
maintained post recovery from these known con-
centrations. We then precipitated 10 patient sam-
ples routinely requested independently for gen-
tamicin, vancomicin and valproate were sele cted 
covering the broadest possible concentration 
range that is encountered for these analytes. The 
patient samples were precipitated by both 100% 
ethanol and polyethylene glycol (PEG), 24 g/100 
mL (Fluka#812160, polyethylene glycol 6000, Sig-
ma Aldrich) separately. Both of these reagents are 
commonly available in most laboratories. Based 
on the chemical structure of gentamicin (made up 
of amino groups attached to glycosides), and van-
comicin (a tricyclic glycopeptide made up of gly-
cans covalently attached to the side chains of the 
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amino acid residues) it was possible PEG would 
not be suitable as it could precipitate these antibi-
otics, hence ethanol was considered as a milder al-
ternative. The samples were processed in a single 
batch for each of the three analytes. Samples were 
mixed with equal volumes of the ethanol or PEG 
solution (0.25 mL : 0.25 mL), vortex mixed, than 
centrifuged (10 min, 3000 x g ), and the superna-
tant removed and analysed. For each sample the 
reaction curve was checked that it was normal to 
ensure there was no paraprotein interference. 
Statistical analysis was performed using the Micro-
soft Excel (Microsoft Corporation, Redmond, WA, 
USA) and Analyse-It statistical add-on for Micro-
soft Excel (Analyse-It Software, Leeds, UK) for the 
Passing Bablok regression analysis. Recovery was 
calculated by subtracting the neat sample result 
from the post precipitation result, and the differ-
ence was then divided by the neat result and mul-
tiplied by 100% to provide the recovery percent-
age. 
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Results
Besides the gentamicin only vancomicin and val-
proate were affected as shown from the absorb-
ance plots, Figure 1. The patient medical record in-
dicated the patient was not on vancomicin or val-
proate. Comparing the reaction curve with the 
normal sample reaction curve it was clear the pre-
cipitation in the gentamicin assay was occurring 
upon addition of the reactive reagents (reagent B 
and C). The vancomicin and valproate plots equal-
ly showed the precipitation was observed upon 
addition of the reactive reagents (vancomicin has 
reagent B and C and valproate only has reagent C) 
(Figure 1E and G).   
The immunoglobulin analysis showed the follow-
ing results: rheumatoid factor < 20 IU/mL (RR < 20); 
IgG 2.39 g/L (RR 7.0-16.0); IgA 2.56 g/L (RR 1.0-4.0); 
and IgM 18.9 g/L (RR 0.4-2.3).  The results con-




Figure 1. Reaction absorbance curves for 1. Gentamicin:  A- normal sample, B -case study neat sample, C-case study 1/20 diluted 
sample; 2. Vancomicin:  D- normal sample, E- case study neat sample; 3. Valproate: F- normal sample, G- case study neat sample.
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ror was induced by the paraprotein (IgM) precipi-
tation (16). 
The Passing Bablok regression correlation results, 
concentration ranges and recovery data is shown 
in Table 1. The PEG precipitation produced unsuit-
able recoveries (mean recovery of <30%) for the 
three analytes. Using the internal quality control 
performance data (two quality control levels per 
each assay) the mean CVs at two standard devia-
tions for each of the assays were: a) gentamicin 
15.2%, b) vancomicin 12.6% and c) valproate 17.8%. 
Hence, the ideal recovery for each assay should 
have been: a) gentamicin 84.8-115.2%, b) vanc-
omicin 87.4-112.6% and c) valproate 82.3-117.8%.   
Discussion
From our searches, no interference has ever been 
reported with gentamicin or valproate turbidimet-
ric assays by a paraprotein. Availability of absorb-
ance curves is a powerful tool to highlighting po-
tential assay problems. What the absorbance 
curves indicated was the precipitation/turbidity 
was occurring in the latter part of the reaction pro-
cess, the non-blanking phase, upon addition of 
the reactive reagents hence for the high absorb-
ance errors. As King et al. also highlight, the re-
verse would occur if the precipitation/turbidity is 
occurring in the blanking stage, and would lead to 
low absorbance errors, low results. This has been 
reported with vancomicin by previous publica-
tions (5,17,18).  
Closer scrutiny of the proteins results, globulins 
specifically on presentation along with the age of 
the patient provided a trigger for further investi-
gation, potential presence of a paraprotein. Al-
though IgG is the most common paraprotein (~59-
70%), followed by IgM (~17%) and IgA (~11-17%) 
(19,20). These paraprotein producing disorders in-
crease with age rising from 3.2% in people < 50 
years of age to 5.3% in people > 70 years of age 
(19), 4.5% in the population in the 45-75 years of 
age (20). Hence the reported paraprotein interfer-
ence problems are in older patients as is the case 
here and from review of literature IgM is most fre-
quently reported to be the cause of interference 
Table 1a. The Passing Bablok regression analysis of concentration ranges and recovery results for the Beckman calibrators treated by 
100% ethanol precipitation versus stated concentrations.
Drug




(0-12 mg/L) 1.12 (0.97-1.16) 0.09 (-0.38-0.01) 0.999 93%;
Vancomicin
(0-50 mg/L) 1.18 (0.96-1.29) -1.94 (-4.07-0.00) 0.995 96%
Vvalproate
(0-150 mg/L) 1.12 (0.90-1.22) -7.13 (-16.20-0.00) 0.996 88%
Table 1b. Comparison of drug concentrations (Passing Bablok regression analysis) measured in native patient samples and samples 
treated by 100% ethanol precipitation, N = 10.
Drug




(1.1-11.9 mg/L) 0.92 (0.65-1.13) 0.20 (-0.34-0.72) 0.951 99%
Vancomicin
(8.1-49.1  mg/L) 0.77 (0.65-0.87) -1.26 (-3.98-1.36) 0.974 72%
Valproate
(12.6-133.0 mg/L) 0.97 (0.75-1.09) -4.64 (-13.33-1.43) 0.981 81%
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by turbidity or precipitation. This in turn was the 
reason we initiated testing of all the turbidimetric 
assays for potential interference. 
The Beckman method inserts state gentamicin, 
vancomicin and valproate were tested with IgM 
concentration up to 5 g/L without effect. In our ex-
perience the IgM concentration level is not the 
sole determinant for precipitation and subsequent 
interference. Precipitation occurs as a result of 
physicochemical conditions (pH, ionic strength, 
presence of surfactants and other chemicals in the 
reagents) being in the right balance, where the pH 
and the isoelectric point being the same and the 
protein charges being neutralised. This balance or 
uniqueness to achieve precipitation can be due to 
the IgM type (lambda or kappa), assay reagents or 
they can be influenced by other compounds like 
heparin (14). Ideally manufacturers should test for 
IgM interference with much higher concentration 
levels e.g. > 15 g/L, specifically with turbidimetric 
assays in order to better challenge the method.  
Review of the Beckman method inserts of the test-
ed turbidimetric assays does not provide ability to 
try and extrapolate as to why only three of the as-
says exhibited interference. The inserts do not 
contain data on the reaction buffer used (reagent 
A), its type or the pH and only minimal data, anti-
body type only on the reactive reagent(s) (reagent 
B or C, or B and C) being used. It is assumed the pH 
of the reactive reagents in these assays was suffi-
cient to achieve the appropriate pI and cause the 
precipitation. The Roche gentamicin method 
showed no interference and this was most likely 
due to the analytical method difference, fluores-
cence polarization type rather than turbidimetric 
as is the Beckman method. 
The available option for laboratories in obtaining 
an accurately representative result is predomi-
nantly to analyse samples on an alternative sys-
tem/method which is not always easily accessible. 
Precipitation of proteins along with the interfering 
protein while retaining the analyte of interest in 
the supernatant is an alternative option. Precipita-
tion can depend on the analyte chemical compo-
sition, and choice of precipitant and its availability. 
In general precipitation is most successful with in-
organic compounds e.g. digoxin (21). With gen-
tamicin and vancomicin containing amino acids 
ethanol was shown to be a suitable precipitant to 
obtain desirable recoveries with the three analytes 
affected in this case. The use of filtration methods 
is another option but they are only readily availa-
ble in a few large laboratories.
Incidences or encounters like this can be a trigger 
to identifying the presence of unidentified patho-
logical abnormalities and there is a need to imme-
diately communicate to clinical staff for best pa-
tient care as was done in this case. A limitation of 
this study was that due to insufficient patient sam-
ples the type of IgM was not determined and nei-
ther was precipitation performed for the gen-
tamicin to compare results to the Roche system. A 
second limitation was the small number (10 pa-
tient samples) tested without paraprotein interfer-
ence, and the larger number of samples could also 
lead to improvement in the recovery.
Not just gentamicin but vancomicin and valproate 
are also associated with potential toxicity and the 
plasma levels need to be monitored. Being able to 
measure analytes’ concentrations and provide re-
sults both timely and accurately is the key to the 
existence of pathology. Having options or tools to 
overcome adversity, namely interferences, in 
house goes a long way to ensuring laboratory ser-
vices are prompt and subsequent patient care de-
cisions are optimised. When interference is detect-
ed with one analyte it is always valuable to run 
such sample on assays using same analytical tech-
niques as the minimum, specifically for immunoas-
say based techniques.   
In summary, the findings from this case showed 
for the first time IgM interference with gentamicin, 
valproate and vancomicin where the interference 
led to high absorbance which has never been re-
ported with these analytes. Equally, it was shown 
ethanol can be used to precipitate proteins and 
produce acceptable recovery results. This allows 
all laboratories to use this technique to overcome 
such interferences. 
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